The Design of a Double-Blind, Placebo-Controlled, Multi-National Phase-Iii Trial in Patients with Parkinson's Disease and End-Of-Dose Motor Fluctuations: Opicapone Superiority Vs. Placebo
AuthID
P-005-5M1
P-005-5M1